ABSTRACT An in vivo murine model for immunodeficiency of both B and T cells is produced by continuous intraperitoneal infusion of 2'-deoxycoformycin (DCF), a specific tightly binding inhibitor of adenosine deaminase (ADase; adenosine aminohydrolase, EC 3.5.4.4). After DCF infusion, ADase of thymus, spleen, and lymph nodes was inhibited to varying degrees ranging from 57% to 100%. Immunodeficiency under these conditions was indicated by: (i) a striking decrease in lymphocyte response to the T-cell mitogens concanavalin A and phytohemagglutinin and the B-cell mitogen Escherichia coli Iipopolysaccharide; (ii) an impairment of delayed hypersensitivity measured by the footpad reaction; (iii) a decrease in antibody production measured in both in vivo and in vitro plaque-forming cell assays; (iv) a significant prolongation of mouse skin allograft survival after transplantation into the C57BL/6J (H-2b) strain of skin from BALB/c (H-2d) mice; and (v) a marked lymphopenia. Histological examination indicated lymphoid degeneration in the thymus, lymph nodes, and spleen with no alterations in other tissues including bone marrow, kidney, lung, gastrointestinal tract, and liver except for the occurrence of hepatitis. A decrease in the number of Thy-i-positive cells in both spleen and lymph nodes further supported the fact of cytotoxicity of DCF to T cells. Anorexia and weight loss were observed within 5 days of continuous DCF infusion at 0.4 mg/kg body weight per day. These data indicate that this method provides an experimental model for future studies on the biochemical mechanisms responsible for the genetically determined severe combined immunodeficiency disease in man. The metabolism of the naturally occurring purine nucleosides adenosine and 2'-deoxyadenosine is of special importance to proper lymphocyte function and differentiation. This relationship is particularly emphasized by reports of children with severe combined immunodeficiency disease (SCID) who also have an inherited deficiency of the enzyme adenosine deaminase (ADase; adenosine aminohydrolase, EC 3.5.4.4) in all tissues (1, 2). SCID is characterized by defects in both humoral and cellular immune functions, which result in death due to infection unless bone marrow is transplanted from a histocompatible donor. A causal relationship between the enzyme defect and the syndrome is supported by the facts that (I) ADase deficiency and SCID are individually rare occurrences, which renders it unlikely that their appearance together is fortuitous; (if) cytostatic and cytotoxic effects of low concentrations of adenosine and 2'-deoxyadenosine on lymphoid cells in culture generally are potentiated by ADase inhibitors (3-5); and (Mi) an inherited deficiency of another enzyme in the pathway of adenosine metabolism, purine nucleoside phosphorylase, is also associated with immunodeficiency (6) . Chromosomal mapping studies argue strongly against a genetic deletion affecting ADase and immune response genes (7, 8) .
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Considerable controversy exists concerning the biochemical mechanism that causes an ADase deficiency to be specifically lymphocytotoxic. Proposals include inhibition of ribonucleoside diphosphate reductase (a critical enzyme in DNA biosynthesis) by increased levels of 2'-deoxyATP (9, 10), pyrimidine starvation produced by increased adenine nucleotides (4) , and increased levels of cyclic 3',5'-AMP, a potent antiproliferative agent (11) . An animal model for immunodeficiency associated with ADase deficiency would be of great value for distinguishing among these possibilities.
2'-Deoxycoformycin (DCF), a microbial fermentation product (12) , is an extremely tightly binding stoichiometric inhibitor of ADase (13) . Histopathological examination of mice receiving a single injection of DCF has indicated a toxicity highly specific to the lymphoid system (14) , and immuriosuppressive activity of DCF in a tumor test system has been reported (15 These data demonstrate that inhibition of ADase without the addition of adenosine or its analogs is sufficient to produce severe immune dysfunction.
MATERIALS AND METHODS
Materials. C57BL/6J (H-2b) and BALB/c (H-2d) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). DCF was a generous gift from the National Cancer Institute through the assistance of J. Douros. Phytohemagglutinin P and Eschenchia coil lipopolysaccharides were purchased from Difco, and concanavalin A was from Calbiochem (San Diego, CA). RPMI-1640 medium, Dulbecco's phosphate-buffered saline (Pi/NaCl), Hariks (Table 2) .
Additional evidence for suppression of T-cell function is the effect of DCF infusion on delayed hypersensitivity reactions The length of survival of skin allografts across major histocompatibility barriers was also used to document depression of cell-mediated immunity (Table 4) . Split-thickness skin from the backs of BALB/c (H-2d) mice was grafted to the right flanks of C57BL (H-2b) mice and the survival time was monitored (22) . Because Spleen cells were sensitized either in vitro by preincubation with SRBC or in vivo by direct intraperitoneal injection of SRBC. Antibody production was determined by counting the number of plaque-forming cells. Plaques formed by control splenocytes preincubated in the absence of SRBC have been subtracted from the data. The rate of DCF infusion was 0.40 and 0.16 mg/kg body weight per day for the in vitro and in vivo procedures, respectively. * The decreases in mean values after DCF infusion were statistically significant (P < 0.05 and P < 0.1 for in vitro and in vivo data, respectively). t Mean + SD of five determinations on cells pooled from three animals, expressed as number of plaques per 1 X 107 splenocytes. Mean + SD of three determinations on individual spleens, expressed as number of plaques per spleen.
immunosuppression, DCF should be infused continuously at low levels until signs of toxicity are apparent. The results from both methods of administration support the view that DCF suppresses cell-mediated immune responses. The effect of DCF infusion on antibody production was characterized by using both in vivo and in vitro plaque-forming assays (21) . The longer period of infusion required for the in vvo procedure again necessitated lowering the dose of DCF from 0.4 to 0.16 mg/kg body weight per day. In both cases the number of antibody-producing cells was significantly depressed (Table 5 ). The depression noted in the in vivo assay, in which the data are expressed as the number of plaques per spleen, is consistent with the loss of spleen weight after DCF treatment (see below). However, the degree of reduction of antibody formation in both assays is greater than can be accounted for by a reduction in the number of B cells. Whether these results reflect a direct interference of DCF with antibody synthesis and/or antigen processing, a suppression of T helper cell function, or both remains to be determined.
Toxicity and Histopathology. Mean (ISD) mouse weights changed from 20.1 t 0.9 g to 15.2 + 1.0 g after a 5-day infusion of DCF, a decrease of -25%; negligible weight change was observed in control animals infused with 0.9% NaCl. A noticeable loss of appetite was observed in the DCF-infused group. Mean splenic weights for a 20-g mouse changed from 0.102 E 0.011 to 0.036 + 0.004, a decrease of about 65%. In comparison, a 28% decrease in splenic weight and a 35% decrease in mean (15, 26) and are specifically lymphocytotoxic (14) . In the latter study, however, lymphopenia was not produced by DCF treatment and the degree of splenic hypoplasia was significantly less than that observed here. No further observations on changes in thymic weight were reported. The extensive immunosuppression and lymphocytotoxicity noted in our studies may be a consequence of the method of DCF administration-i.e., continuous intraperitoneal infusion over a prolonged period. This conclusion is consistent with previous data from our laboratory implying that ADase in certain tissues may be inducible in response to the presence of an inhibitor (16, 27) as well as with reports of a recovery of ADase level after a single injection of DCF (17, 18) . This regeneration of enzyme activity, which may occur by synthesis of new protein or turnover of cells, is aided by the rapid clearance of DCF from the plasma (17, 28 (3, (30) (31) (32) (33) (34) . Although there is variability in the data, these studies are in general agreement that concentrations of the inhibitors that depress enzyme activity do not markedly affect the proliferative response to mitogens, whereas high concentrations of adenosine are strongly antiproliferative. The combination of adenosine and an ADase inhibitor in these systems, however, was shown to act synergistically in inhibiting mitogen-induced blastogenesis. The murine model described here differs significantly in that administration of an ADase inhibitor alone is sufficient to produce a profound immunosuppression. This experimental system seems to represent an accurate model of human SCID associated with ADase deficiency and should provide a means for analyzing the biochemical relationship between the ADase deficiency and the immunodeficiency with which it is associated.
